January 02, 2019
WELLESLEY, Mass., Jan. 02, 2019 – Owing to the rising number of new lung cancer cases, the increasing geriatric population, the rise in tobacco smokers and increased exposure to environmental carcinogens, the global lung cancer therapeutics market has seen ample growth in recent years, according to BCC Research.
According to the report “Lung Cancer Therapeutics: Global Markets,” the global market for lung cancer therapeutics was valued at $17.9 billion in 2018 and is expected to reach $26.3 billion by 2023, growing at a compound annual growth rate (CAGR) of 8.0% during the forecast period.
Prominent players in the industry include: Eli Lilly and Co. (LLY), Pfizer Inc. (PFE), Roche Holding AG (RHHBY), AstraZeneca plc (AZNCF), Novartis International AG (NVS) and Merck & Co. Inc. (MRK), among others.
“Funding for lung cancer research is critical due to the disease’s prominence and because doctors often find lung cancer in later stages when it’s less treatable,” the report notes. “New advances hold great promise for screening, early detection and personalized therapies.”
Patent Expiration of Key Drug Molecules as a Market Restraint
Generics play a vital role in the healthcare system. After the loss of patent exclusivity, the entry of generic versions into the market is likely to lower the price of the drug molecule due to competitive pricing. To encourage the entry of generic entities, the FDA currently offers a period of marketing exclusivity of 180 days (known as the Hatch-Waxman Act) to the first pharmaceutical firm that obtains approval for a generic version of a branded drug.
Editors/reporters requesting analyst interviews should contact Eric Surber at email@example.com.
Lung Cancer Therapeutics: Global Markets( PHM206A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.